Drug-eluting stent: Where is the way out?

Chinese Medical Journal

Volumn 126, Issue 6, 2013, Pages 1005-1007

  Han, Ya Ling ^a  

^a SHENYANG NORTHERN HOSPITAL   (China)

Author keywords

Abluminal coating; Drut eluting stent; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

BIODEGRADABILITY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG RELEASE; EDITORIAL; GENDER; HUMAN; INFLAMMATION; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; STENT THROMBOSIS;

DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84876932465     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130440     Document Type: Editorial

References (24)

1. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440-1455.
2. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
3. Garg S, Serruys PW. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2010; 8: 449-470.
4. Garg S, Serruys PW, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, et al. Three year clinical follow up of the XIENCE V Everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. The SPIRIT II Trial. J Am Coll Cardiol Intv 2009; 2: 1190-1198.
5. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Randomized comparison of everolimus-elutmg and pachtaxel-eluting stents: 2-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
6. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, et al. Companson of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009; 120: 141-149, 1-2.
7. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or pachtaxel-eluting stents. Circulation 2005; 112: 270-278.
8. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342.
9. Niemela KO. Biodegradable coating for drug-eluting stents-more than a facelift? Eur Heart J 2008; 29: 1930-1931.
10. Kan J, Chen F, Liu LY, Xu HM, Lin L, Liu Y, et al. Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation. Chin Med J 2013; 126: 1081-1085.
11. Zhang L, Qiao B, Han YL, Li Y, Xu K, Zhang QY, et al. Gender difference on 5-year outcomes of EXCEL biodegradable polymer-coated sirolimus-eluting stents implantation: results from the CREATE study. Chin Med J 2013; 126: 1039-1045.
12. Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Mdei M, et al. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv 2009; 74: 719-727.
13. Berger JS, Sanborn TA, Sherman W, Brown DL. Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention. Am Heart J 2006; 151: 1026-1031.
14. Kovacic JC, Mehran R, Karajgikar R, Baber U, Suleman J, Kim MC, et al. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv 2012; 80: 514-521.
15. Tillmanns H, Waas W, Voss R, Grempels E, Hölschermann H, Haberbosch W, et al. Gender differences in the outcome of cardiac interventions. Herz 2005; 30: 375-389.
16. Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98: 1279-1285.
17. Han YL, Zhang L, Yang LX, Liu HL, Qu P, Li WM, et al. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. EuroIntervention 2012; 8: 815-822.
18. Han Y, Jing Q, Li Y, Yang L, Liu H, Shang X, et al. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. Catheter Cardiovasc Interv 2012; 79: 211-216.
19. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.
20. Xu B, Gao RL, Zhang RY, Wang HC, Li ZQ, Yang YJ, et al. Efficacy and safety of FIREHAWK®abluminal groove filled biodegradable polymer sirolimus-eluting stent for the treatment of long coronary lesions: 9-month angiographic and 1-year clinical results from TARGET I trial long cohort. Chin Med J 2013; 126: 1026-1032.
21. Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, et al. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chin Med J 2012; 125: 970-976.
22. Xu B, Dou KF, Han YL, Lu SZ, Yang YJ, Huo Y, et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J 2011; 124: 811-816.
23. Qiao SB, Hou Q, Xu B, Yang YJ, Chen JL, Gao RL. The clinical efficacy of sirolimus-eluting stents versus pachtaxel-eluting stents in complex and diffuse coronary lesions. Chin J Intern Med (Chin) 2006; 45: 985-987.
24. Xiang D, Yi S, Ruan Y, Gong Z, Hong C, Qiu J. Comparison of angiographic and IVUS follow-up between the two different drug-eluting stents implanted simultaneously in the same individuals. J Invasive Cardiol 2012; 24: 374.